Fig. 3.

The relative efficacies of 5-HT_2A receptor agonists are globally augmented by genetic deletion of RSK2. Agonist potencies (pEC₅₀) and relative efficacies (E_max) for IP accumulation (A and B), Ca²⁺ release (C and D), and ERK phosphorylation (E and F) in WT and RSK2 KO MEFs were plotted as X–Y correlations. Relative to a line of identity (dashed line), E_max values were consistently higher in RSK2 KO MEFs, whereas pEC₅₀ values were similar between cell lines. E_max and pEC₅₀ values were calculated via nonlinear regression as reported in Tables 1 to 3. Values represent the mean ± S.E.M. of three to six independent experiments performed in duplicate. Agonists tested were 5-HT (■), DOI (□), quipazine (●), 5-methoxy-DMT (○), lisuride (▴), m-CPP (▵), SCH-23390 (▾), α-Me-5-HT (▿), and MK212 (♦).